Ken Griffin Amgen Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Amgen Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 1,014,700 shares of AMGN stock, worth $288 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

1,014,700

Previous 1,432,100 29.15%

Holding current value

$288 Million

Previous $447 Million 26.93%

% of portfolio

0.06%

Previous 0.09%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$309.38 - $337.38 $4.64 Million - $5.06 Million	-15,010 Reduced 65.79%	7,804 $2.51 Million
Q2 2024 Aug 14, 2024	SELL	$262.75 - $319.31 $27.7 Million - $33.6 Million	-105,368 Reduced 82.2%	22,814 $7.13 Million
Q1 2024 May 15, 2024	BUY	$268.87 - $324.56 $34.5 Million - $41.6 Million	128,182 New	128,182 $36.4 Million
Q3 2023 Nov 14, 2023	SELL	$218.65 - $271.46 $71.4 Million - $88.6 Million	-326,544 Reduced 88.85%	40,987 $11 Million
Q2 2023 Aug 14, 2023	BUY	$214.27 - $253.37 $14.2 Million - $16.7 Million	66,044 Added 21.91%	367,531 $81.6 Million
Q1 2023 May 15, 2023	BUY	$225.79 - $275.2 $53.3 Million - $64.9 Million	235,907 Added 359.72%	301,487 $72.9 Million
Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $11.4 Million - $14.4 Million	-49,638 Reduced 43.08%	65,580 $17.2 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $64 Million - $72.2 Million	-285,026 Reduced 71.21%	115,218 $26 Million
Q2 2022 Aug 15, 2022	BUY	$230.71 - $256.74 $24.3 Million - $27 Million	105,276 Added 35.69%	400,244 $97.4 Million
Q1 2022 May 16, 2022	SELL	$219.27 - $242.57 $15.8 Million - $17.5 Million	-72,064 Reduced 19.63%	294,968 $71.3 Million
Q4 2021 Feb 14, 2022	BUY	$198.88 - $227.6 $18 Million - $20.6 Million	90,446 Added 32.7%	367,032 $82.6 Million
Q3 2021 Nov 15, 2021	SELL	$212.27 - $248.7 $50.7 Million - $59.4 Million	-239,028 Reduced 46.36%	276,586 $58.8 Million
Q2 2021 Aug 16, 2021	BUY	$233.58 - $259.14 $82.1 Million - $91.1 Million	351,638 Added 214.44%	515,614 $126 Million
Q1 2021 May 17, 2021	SELL	$221.91 - $258.6 $15.2 Million - $17.8 Million	-68,716 Reduced 29.53%	163,976 $40.8 Million
Q4 2020 Feb 16, 2021	SELL	$216.38 - $257.67 $28 Million - $33.4 Million	-129,449 Reduced 35.75%	232,692 $53.5 Million
Q3 2020 Nov 16, 2020	SELL	$234.65 - $260.95 $144 Million - $160 Million	-612,146 Reduced 62.83%	362,141 $92 Million
Q2 2020 Aug 14, 2020	BUY	$197.81 - $242.74 $157 Million - $193 Million	795,290 Added 444.3%	974,287 $230 Million
Q1 2020 May 15, 2020	SELL	$182.24 - $241.7 $12.8 Million - $17 Million	-70,299 Reduced 28.2%	178,997 $36.3 Million
Q4 2019 Feb 14, 2020	SELL	$189.21 - $243.2 $145 Million - $186 Million	-764,108 Reduced 75.4%	249,296 $60.1 Million
Q3 2019 Nov 14, 2019	BUY	$174.11 - $208.62 $137 Million - $164 Million	785,948 Added 345.54%	1,013,404 $196 Million
Q2 2019 Aug 14, 2019	BUY	$166.7 - $195.41 $5.64 Million - $6.61 Million	33,836 Added 17.48%	227,456 $41.9 Million
Q1 2019 May 15, 2019	SELL	$180.87 - $203.88 $21.4 Million - $24.1 Million	-118,102 Reduced 37.89%	193,620 $0
Q4 2018 Feb 14, 2019	BUY	$178.4 - $208.25 $37 Million - $43.1 Million	207,138 Added 198.06%	311,722 $60.7 Million
Q3 2018 Nov 13, 2018	SELL	$185.29 - $208.89 $3.59 Million - $4.05 Million	-19,400 Reduced 15.65%	104,584 $0
Q2 2018 Aug 10, 2018	BUY	$166.05 - $186.51 $2.43 Million - $2.73 Million	14,658 Added 13.41%	123,984 $0
Q1 2018 May 11, 2018	SELL	$169.43 - $198.0 $17.1 Million - $20 Million	-100,799 Reduced 47.97%	109,326 $18.6 Million
Q4 2017 Feb 09, 2018	BUY	$168.79 - $188.59 $31.5 Million - $35.2 Million	186,858 Added 803.1%	210,125 $36.5 Million
Q3 2017 Nov 09, 2017	BUY	$167.29 - $191.0 $3.89 Million - $4.44 Million	23,267	23,267 $4.34 Million

Others Institutions Holding AMGN

# of Institutions

3,113

Shares Held

410M

Call Options Held

Put Options Held

6.15M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $152B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account